These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 9421401

  • 1. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism.
    Yoshimoto T, Naruse M, Tanabe A, Naruse K, Seki T, Imaki T, Muraki T, Matsuda Y, Demura H.
    Endocrinology; 1998 Jan; 139(1):81-8. PubMed ID: 9421401
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart.
    Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe T, Hanawa H, Kato K, Kodama M, Aizawa Y.
    J Cardiovasc Pharmacol; 2000 Jan; 36 Suppl 2():S19-23. PubMed ID: 11206715
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Increased cyclic guanosine monophosphate production and overexpression of atrial natriuretic peptide A-receptor mRNA in spontaneously hypertensive rats.
    Tremblay J, Huot C, Willenbrock RC, Bayard F, Gossard F, Fujio N, Koch C, Kuchel O, Debinski W, Hamet P.
    J Clin Invest; 1993 Nov; 92(5):2499-508. PubMed ID: 7901238
    [Abstract] [Full Text] [Related]

  • 6. Vascular action of circulating and local natriuretic peptide systems is potentiated in obese/hyperglycemic and hypertensive rats.
    Yoshimoto T, Naruse M, Naruse K, Arai K, Imaki T, Tanabe A, Seki T, Hirose S, Muraki T, Demura H.
    Endocrinology; 1996 Dec; 137(12):5552-7. PubMed ID: 8940383
    [Abstract] [Full Text] [Related]

  • 7. Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise.
    Omvik P, Lund-Johansen P, Myking O.
    J Cardiovasc Pharmacol; 1992 Dec; 19 Suppl 1():S90-6. PubMed ID: 1378157
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Angiotensin II-dependent down-regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats.
    Yoshimoto T, Naruse M, Naruse K, Shionoya K, Tanaka M, Tanabe A, Hagiwara H, Hirose S, Muraki T, Demura H.
    Endocrinology; 1996 Mar; 137(3):1102-7. PubMed ID: 8603580
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Natriuretic peptide clearance receptor is transcriptionally down-regulated by beta 2-adrenergic stimulation in vascular smooth muscle cells.
    Kishimoto I, Yoshimasa T, Suga S, Ogawa Y, Komatsu Y, Nakagawa O, Itoh H, Nakao K.
    J Biol Chem; 1994 Nov 11; 269(45):28300-8. PubMed ID: 7961768
    [Abstract] [Full Text] [Related]

  • 13. The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
    Albrecht M, Haustein KO.
    Int J Clin Pharmacol Ther; 1997 Dec 11; 35(12):580-6. PubMed ID: 9455718
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
    Nichols AJ, Gellai M, Ruffolo RR.
    Fundam Clin Pharmacol; 1991 Dec 11; 5(1):25-38. PubMed ID: 1712335
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin converting enzyme inhibitor but not calcium blocker down-regulates gene expression of vascular natriuretic peptide receptor in hypertensive rats.
    Yoshimoto T, Naruse M, Tanabe A, Naruse K, Takagi K, Muraki T, Itakura M, Hagiwara H, Hirose S, Demura H.
    Biochem Biophys Res Commun; 1994 Dec 30; 205(3):1595-600. PubMed ID: 7811241
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability.
    Bertera FM, Del Mauro JS, Chiappetta D, Polizio AH, Buontempo F, Taira CA, Höcht C.
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Mar 30; 385(3):325-35. PubMed ID: 22048841
    [Abstract] [Full Text] [Related]

  • 20. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
    Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H.
    J Biomed Sci; 2005 Mar 30; 12(2):409-20. PubMed ID: 15942707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.